Growth Hormone Secretagogue MK-0677 Effect on IGF-1 Levels in ESRD Patients

NACompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 31, 2006

Primary Completion Date

January 31, 2009

Study Completion Date

May 31, 2010

Conditions

Chronic Kidney DiseaseEnd Stage Renal Disease

Interventions

DRUG

MK-0677

The dosage of the drug is 25mg, subjects will take one pill a day for about 30 days.

DRUG

Placebo

Trial Locations (1)

University of Virginia, Charlottesville

All Listed Sponsors

collaborator

National Institutes of Health (NIH)

NIH

collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

University of Virginia

OTHER

NCT00395291 - Growth Hormone Secretagogue MK-0677 Effect on IGF-1 Levels in ESRD Patients | Biotech Hunter | Biotech Hunter